Whereas only 12 venture capital transactions were conducted in 2016, the number of transactions in 2021 (YTD) have almost five-folded to 56.
In addition, US and European companies from the psychedelic space were able to attract significantly higher volumes in the last five years. The transaction volume has almost ten-folded, from EUR 53m in 2016 to EUR 489m in 2021 (YTD).
About FCF Life Sciences
FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.
Learn more about FCF Life Sciences, click here.
We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.
To hear from us on the latest insights, please sign up here: